FUTURE PLANS

For a detailed description of our future plans, see "Business — Strategy."

USE OF [REDACTED]

Assuming an [**REDACTED**] of HK$[**REDACTED**] per H Share (being the midpoint of the range of the [**REDACTED**] stated in this document), we estimate that we will receive net [**REDACTED**] of approximately HK$[**REDACTED**] from the [**REDACTED**] after deducting the [**REDACTED**] commissions and other estimated expenses paid and payable by us in connection with the [**REDACTED**] and assuming that the [**REDACTED**] is not exercised. In line with our strategies, we intend to use our net [**REDACTED**] for the purposes and in the amounts set forth below.

- approximately [**REDACTED**]% of the net [**REDACTED**], or approximately HK$[**REDACTED**], will be allocated to fund the research, development, and commercialization of our core vaccine candidates in the upcoming three years:
  - approximately [**REDACTED**]%, or approximately HK$[**REDACTED**], will be used to fund the final-stage development and NDA work for our PCV13 candidate. These funds will support the completion of the ongoing Phase III clinical trial and the pre-commercialization activities to prepare for its anticipate commercialization in 2027.
  - approximately [**REDACTED**]%, or approximately HK$[**REDACTED**], will be used to fund the ongoing clinical development of our PCV24 candidate. These funds will support the ongoing Phase I clinical trial and advance the candidate through subsequent clinical phases.
  - approximately [**REDACTED**]%, or approximately HK$[**REDACTED**], will be used to fund the clinical development of our lyophilized human rabies vaccine (HDC) candidate. These funds will be primarily used to advance this candidate's Phase III clinical trial, and to support its registration and preparation for its expected commencement of commercialization in 2028.
- approximately [**REDACTED**]% of the net [**REDACTED**], or approximately HK$[**REDACTED**], will be allocated to advance the research and development of other key vaccine candidates in our pipeline in the upcoming three years, including PPSV23, MenB, MCV4 and trivalent influenza subunit vaccine (MDCK cell) candidates;
- approximately [**REDACTED**]% of the net [**REDACTED**], or approximately HK$[**REDACTED**], will be allocated to the construction and upgrade of our manufacturing facilities to support the future commercial launch of certain of our pipeline products in the upcoming three years, which will be used for the expansion of our Chengdu facility. This facility is designated as our primary site for bacterial vaccines, and this investment will support the build-out of production lines and procurement of equipment for our pneumococcal and meningococcal vaccine candidates;
- approximately [**REDACTED**]% of the net [**REDACTED**], or approximately HK$[**REDACTED**], will be allocated for overseas expansion and potential strategic acquisitions or in-licensing opportunities in the upcoming three years:
  - approximately [**REDACTED**]%, or approximately HK$[**REDACTED**], will be allocated for the potential in-licensing and domestic distribution of a vaccine product from overseas partners. These funds will support our strategy to act as the partner of choice for global pharmaceutical companies by leveraging our qualification to act as a domestic agent for imported vaccines, allowing us to broaden our portfolio with innovative products that address unmet clinical needs in China.

  - o approximately [**REDACTED**]%, or approximately HK$[**REDACTED**], will be used to actively explore and fund strategic business development opportunities. This includes the potential in-licensing or acquisition of complementary vaccine candidates or platform technologies from other domestic companies that have the potential to address unmet needs in China.

- approximately [**REDACTED**]% of the net [**REDACTED**], or approximately HK$[**REDACTED**], is expected to be used for working capital and general corporate purposes.

In the event that the [**REDACTED**] is set at the maximum [**REDACTED**] or the minimum [**REDACTED**] of the indicative [**REDACTED**] range, the net [**REDACTED**] of the [**REDACTED**] will increase or decrease by approximately HK$[**REDACTED**], respectively. We intend to apply the additional or reduced net [**REDACTED**] to the above uses on a pro rata basis.

The additional net [**REDACTED**] that we would receive if the [**REDACTED**] was exercised in full would be (i) HK$[**REDACTED**] (assuming an [**REDACTED**] of HK$[**REDACTED**] per H Share, being the maximum [**REDACTED**]), (ii) HK$[**REDACTED**] (assuming an [**REDACTED**] of HK$[**REDACTED**] per H Share, being the mid-point of the [**REDACTED**] range) and (iii) HK$[**REDACTED**] (assuming an [**REDACTED**] of HK$[**REDACTED**] per H Share, being the minimum [**REDACTED**]).

To the extent that the net [**REDACTED**] from the [**REDACTED**] are not immediately applied to the above purposes and to the extent permitted by applicable law and regulations, we will only hold such funds in short-term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions (as defined under the Securities and Futures Ordinance or the applicable laws and regulations in other jurisdictions). We will issue an appropriate announcement if there is any material change to the above use of [**REDACTED**].